vs
Side-by-side financial comparison of Korro Bio, Inc. (KRRO) and Marathon Bancorp, Inc. (MBBC). Click either name above to swap in a different company.
Marathon Bancorp, Inc. is the larger business by last-quarter revenue ($2.2M vs $1.3M, roughly 1.7× Korro Bio, Inc.). On growth, Marathon Bancorp, Inc. posted the faster year-over-year revenue change (41.7% vs -43.1%). Marathon Bancorp, Inc. produced more free cash flow last quarter ($1.4M vs $-79.1M).
Korro Bio, Inc. is a clinical-stage biotechnology company focused on developing innovative RNA editing therapies for rare and severe genetic diseases. It leverages its proprietary oligonucleotide platform to target disease-causing mutations, with core pipelines covering ophthalmology, respiratory and neuromuscular disorder segments, striving to address unmet medical needs for global patients.
Marathon Bancorp, Inc. is a Maryland-based financial holding company that primarily operates through its community bank subsidiary. It offers a full range of retail and commercial banking products including deposit accounts, consumer loans, commercial mortgages, and small business financing, serving individual and small-to-medium enterprise customers across local markets in Maryland.
KRRO vs MBBC — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.3M | $2.2M |
| Net Profit | — | $501.4K |
| Gross Margin | — | — |
| Operating Margin | — | 26.2% |
| Net Margin | — | 22.3% |
| Revenue YoY | -43.1% | 41.7% |
| Net Profit YoY | -136.1% | 880.7% |
| EPS (diluted) | — | $0.19 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.3M | $2.2M | ||
| Q3 25 | $1.1M | $2.1M | ||
| Q2 25 | $1.5M | $1.9M | ||
| Q1 25 | $2.5M | $1.7M | ||
| Q4 24 | — | $1.6M | ||
| Q3 24 | $0 | $1.6M | ||
| Q2 24 | $0 | $1.6M | ||
| Q1 24 | $0 | $1.6M |
| Q4 25 | — | $501.4K | ||
| Q3 25 | $-18.1M | $444.3K | ||
| Q2 25 | $-25.8M | $-332.0K | ||
| Q1 25 | $-23.4M | $148.4K | ||
| Q4 24 | — | $51.1K | ||
| Q3 24 | $-21.0M | $174.9K | ||
| Q2 24 | $-21.8M | $85.8K | ||
| Q1 24 | $-19.6M | $-631.1K |
| Q4 25 | — | 26.2% | ||
| Q3 25 | -1764.9% | 25.5% | ||
| Q2 25 | -1863.2% | -25.7% | ||
| Q1 25 | -981.2% | 11.6% | ||
| Q4 24 | — | 3.3% | ||
| Q3 24 | — | 13.4% | ||
| Q2 24 | — | 4.1% | ||
| Q1 24 | — | -53.7% |
| Q4 25 | — | 22.3% | ||
| Q3 25 | -1657.0% | 20.7% | ||
| Q2 25 | -1765.1% | -18.9% | ||
| Q1 25 | -917.1% | 8.9% | ||
| Q4 24 | — | 3.2% | ||
| Q3 24 | — | 10.8% | ||
| Q2 24 | — | 6.2% | ||
| Q1 24 | — | -40.7% |
| Q4 25 | — | $0.19 | ||
| Q3 25 | $-1.92 | $0.17 | ||
| Q2 25 | $-2.74 | $-0.13 | ||
| Q1 25 | $-2.49 | $0.07 | ||
| Q4 24 | — | $0.02 | ||
| Q3 24 | $-2.26 | $0.06 | ||
| Q2 24 | $-2.43 | $0.07 | ||
| Q1 24 | $-2.44 | $-0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $75.2M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $51.4M | $46.9M |
| Total Assets | $113.5M | $248.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $75.2M | — | ||
| Q3 25 | $92.5M | — | ||
| Q2 25 | $96.4M | — | ||
| Q1 25 | $115.0M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $137.0M | — | ||
| Q2 24 | $157.4M | — | ||
| Q1 24 | $138.8M | — |
| Q4 25 | $51.4M | $46.9M | ||
| Q3 25 | $99.0M | $46.3M | ||
| Q2 25 | $115.1M | $45.7M | ||
| Q1 25 | $139.0M | $32.0M | ||
| Q4 24 | — | $31.7M | ||
| Q3 24 | $179.6M | $31.6M | ||
| Q2 24 | $198.1M | $31.3M | ||
| Q1 24 | $151.4M | $31.4M |
| Q4 25 | $113.5M | $248.0M | ||
| Q3 25 | $161.6M | $246.0M | ||
| Q2 25 | $180.4M | $238.8M | ||
| Q1 25 | $202.2M | $236.8M | ||
| Q4 24 | — | $217.9M | ||
| Q3 24 | $243.5M | $216.5M | ||
| Q2 24 | $249.6M | $219.3M | ||
| Q1 24 | $198.0M | $225.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-78.6M | $1.4M |
| Free Cash FlowOCF − Capex | $-79.1M | $1.4M |
| FCF MarginFCF / Revenue | -6120.7% | 62.3% |
| Capex IntensityCapex / Revenue | 40.1% | 0.6% |
| Cash ConversionOCF / Net Profit | — | 2.82× |
| TTM Free Cash FlowTrailing 4 quarters | $-140.4M | $3.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-78.6M | $1.4M | ||
| Q3 25 | $-17.2M | $464.0K | ||
| Q2 25 | $-19.2M | $1.4M | ||
| Q1 25 | $-24.5M | $849.0K | ||
| Q4 24 | — | $113.6K | ||
| Q3 24 | $-16.1M | $945.2K | ||
| Q2 24 | $-14.6M | $416.6K | ||
| Q1 24 | $-21.9M | $-802.1K |
| Q4 25 | $-79.1M | $1.4M | ||
| Q3 25 | $-17.4M | $456.6K | ||
| Q2 25 | $-19.4M | $1.3M | ||
| Q1 25 | $-24.6M | $773.2K | ||
| Q4 24 | — | $105.0K | ||
| Q3 24 | $-21.0M | $921.6K | ||
| Q2 24 | $-20.6M | $-1.8M | ||
| Q1 24 | $-27.5M | $-1.1M |
| Q4 25 | -6120.7% | 62.3% | ||
| Q3 25 | -1592.1% | 21.3% | ||
| Q2 25 | -1326.6% | 66.0% | ||
| Q1 25 | -963.6% | 46.3% | ||
| Q4 24 | — | 6.6% | ||
| Q3 24 | — | 57.1% | ||
| Q2 24 | — | -118.5% | ||
| Q1 24 | — | -67.9% |
| Q4 25 | 40.1% | 0.6% | ||
| Q3 25 | 16.1% | 0.3% | ||
| Q2 25 | 9.6% | 9.3% | ||
| Q1 25 | 4.7% | 4.5% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | — | 1.5% | ||
| Q2 24 | — | 145.2% | ||
| Q1 24 | — | 16.2% |
| Q4 25 | — | 2.82× | ||
| Q3 25 | — | 1.04× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.72× | ||
| Q4 24 | — | 2.22× | ||
| Q3 24 | — | 5.40× | ||
| Q2 24 | — | 4.85× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
